Stratos Wealth Partners’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Stratos Wealth Partners’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-3,873	Closed	-$309K	–	1254
2022 Q2	$309K	Sell	3,873 -821	-17%	-$77.7K	0.01%	920
2022 Q1	$494K	Sell	4,694 -874	-16%	-$85.2K	0.01%	818
2021 Q4	$600K	Buy	5,568 +38	+0.7%	+$4.14K	0.01%	743
2021 Q3	$606K	Buy	5,530 +159	+3%	+$16.5K	0.02%	689
2021 Q2	$503K	Sell	5,371 -1,226	-19%	-$113K	0.01%	770
2021 Q1	$607K	Sell	6,597 -639	-9%	-$53.9K	0.02%	653
2020 Q4	$529K	Sell	7,236 -2,392	-25%	-$178K	0.02%	660
2020 Q3	$748K	Buy	+9,628	New	+$662K	0.02%	493
2018 Q4	–	Sell	-2,000	Closed	-$39K	–	2932
2018 Q3	$39K	Buy	+2,000	New	+$38K	﹤0.01%	1572
2018 Q2	–	Sell	-2,750	Closed	-$39K	–	3017
2018 Q1	$39K	Sell	2,750 -5,300	-66%	-$78.3K	﹤0.01%	1705
2017 Q4	$118K	Buy	+8,050	New	+$113K	0.01%	1095

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Stratos Wealth Partners's HZNP Position: Q3 2022 in Review

Stratos Wealth Partners sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 3,873 shares — an estimated $309K sold.

Stratos Wealth Partners first reported a position in HZNP in Q4 2017 and held it in 11 quarters. The position peaked at $748K in Q3 2020. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Stratos Wealth Partners reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Stratos Wealth Partners sold 3,873 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $309K.
Stratos Wealth Partners first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2017 and held it in 11 quarters.
Stratos Wealth Partners's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $748K in Q3 2020.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Stratos Wealth Partners's 13F filing for Q3 2022, filed 24 Oct 2022.